Benzalkonium chloride foruse in treating conjunctivitis and/or covid-19
AssigneeBausch + Lomb Ireland Limited
InventorsPatrick MCCORMICK, Kimberly MILLARD
Life of this patent
Estimating the term…
Abstract
Methods for treating coronavirus disease 2019 (COVID-19), including at least one ocular manifestation of COVID-19, methods for treating conjunctivitis, and methods for reducing COVID-19 transmission comprising administering an effective amount of benzalkonium chloride are disclosed. Pharmaceutical compositions comprising benzalkonium chloride are also disclosed.
Claims72
A method for treating at least one ocular manifestation of coronavirus disease 2019 (COVID-19) comprising administering to a subject in need thereof an effective amount of benzalkonium chloride.
A method for reducing a risk of SARS-CoV-2 ocular transmission comprising administering to a subject in need thereof an effective amount of benzalkonium chloride.
A method for preventing coronavirus disease 2019 (COVID-19) comprising administering to a subject in need thereof an effective amount of benzalkonium chloride.
A method for reducing an ocular SARS-CoV-2 viral load comprising administering to a subject in need thereof an effective amount of benzalkonium chloride.
A method for treating conjunctivitis comprising administering to a subject in need thereof an effective amount of benzalkonium chloride.
A method for preventing conjunctivitis comprising administering to a subject in need thereof an effective amount of benzalkonium chloride.
A method for reducing an intranasal SARS-CoV-2 viral load comprising administering to a subject in need thereof an effective amount of benzalkonium chloride.
A method for treating or preventing coronavirus disease 2019 (COVID-19) comprising intranasally administering to a subject in need thereof an effective amount of benzalkonium chloride.
Dependencies are inferred from the claim text.